Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program (Jan, 10.1038/s41388-022-02585-3, 2023)

被引：0
|
作者：
Bello Roufai, D.
Goncalves, A.
de la Motte Rouge, T.
Akla, S.
Blonz, C.
Grenier, J.
Gligorov, J.
Saghatchian, M.
Bailleux, C.
Simon, H.
Desmoulins, I.
Tharin, Z.
Renaud, E.
Bertho, M.
Benderra, M-a
Delaloge, S.
Robert, L.
Cottu, P.
Pierga, J. Y.
Loirat, D.
Bertucci, A.
Renouf, B.
Bidard, F. C.
Lerebours, F.
机构：
[1] Institut Curie,Department of Medical Oncology
[2] Institut Paoli Calmettes,Aix
[3] CRCM,Marseille Univ, CNRS, INSERM, Department of Medical Oncology
[4] Centre Eugène Marquis,Department of Medical Oncology
[5] Gustave Roussy,Department of Cancer Medicine
[6] Institut de Cancérologie de l’Ouest,Department of Medical Oncology
[7] Institut du Cancer d’Avignon,Department of Medical Oncology
[8] Hôpital Tenon,Department of Medical Oncology
[9] AP-HP,Breast Cancer Unit
[10] American Hospital of Paris,Department of Medical Oncology
[11] Centre Antoine Lacassagne,Department of Medical Oncology
[12] University Hospital of Brest,Department of Medical Oncology
[13] Centre Georges-François Leclerc,INSERM U938, Institut Universitaire de Cancérologie
[14] UVSQ,undefined
[15] Paris-Saclay University,undefined
[16] Paris Cité University,undefined
[17] AP-HP Sorbonne Université,undefined
来源：
ONCOGENE | 2023年 / 42卷 / 17期
关键词：
D O I：
10.1038/s41388-023-02615-8
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
引用
收藏
页码：1417 / 1417
页数：1
相关论文
共 50 条
  • [21] Sapanisertib Plus Exemestane or Fulvestrant in Women with Hormone Receptor-Positive/HER2-Negative Advanced or Metastatic Breast Cancer
    Lim, Bora
    Potter, David A.
    Salkeni, Mohamad A.
    Silverman, Paula
    Haddad, Tufia C.
    Forget, Frederic
    Awada, Ahmad
    Canon, Jean-Luc
    Danso, Michael
    Lortholary, Alain
    Bourgeois, Hugues
    Tan-Chiu, Elizabeth
    Vincent, Sylvie
    Bahamon, Brittany
    Galinsky, Kevin J.
    Patel, Chirag
    Neuwirth, Rachel
    Leonard, E. Jane
    Diamond, Jennifer R.
    CLINICAL CANCER RESEARCH, 2021, 27 (12) : 3329 - 3338
  • [22] Alpelisib Plus Fulvestrant or Letrozole Demonstrates Sustained Benefits Across Subgroups of Patients with PIK3CA-Mutated HR+/HER2-Advanced Breast Cancer
    Jacobson, Anne
    ONCOLOGIST, 2022, 27 (SUPPL 1): : S13 - S14
  • [23] Alpelisib Plus Fulvestrant or Letrozole Demonstrates Sustained Benefits Across Subgroups of Patients with PIK3CA-Mutated HR+/HER2-Advanced Breast Cancer
    Jacobson, Anne
    ONCOLOGIST, 2022, 27 : S13 - S14
  • [24] INAVO121: Phase III study of inavolisib (INAVO) plus fulvestrant (FUL) vs. alpelisib (ALP) plus FUL in patients (pts) with hormone receptor-positive, HER2-negative (HR+, HER2-) PIK3CA-mutated (mut) locally advanced or metastatic breast cancer (LA/mBC)
    Juric, Dejan
    Kalinsky, Kevin
    Im, Seock-Ah
    Ciruelos, Eva M.
    Bianchini, Giampaolo
    Barrios, Carlos H.
    Jacot, William
    Schmid, Peter
    Loi, Sherene
    Rugo, Hope S.
    Craine, Veronica
    Hutchinson, Katherine E.
    Flechais, Aulde
    Thanopoulou, Eirini
    Harbeck, Nadia
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [25] INAVO121: Phase III study of inavolisib (INAVO) plus fulvestrant (FUL) vs. alpelisib (ALP) plus FUL in patients (pts) with hormone receptor-positive, HER2-negative (HR+, HER2-), PIK3CA-mutated (mut) locally advanced or metastatic breast cancer (LA/mBC)
    Juric, Dejan
    Kalinsky, Kevin
    Im, Seock-Ah
    Ciruelos, Eva
    Bianchini, Giampaolo
    Barrios, Carlos H., Sr.
    Jacot, William
    Schmid, Peter
    Loi, Sherene
    Rugo, Hope S.
    Craine, Veronica
    Hutchinson, Katherine E.
    Flechais, Aulde
    Thanopoulou, Eirini
    Harbeck, Nadia
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [26] Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial
    Dent, S.
    Cortes, J.
    Im, Y-H
    Dieras, V
    Harbeck, N.
    Krop, I. E.
    Wilson, T. R.
    Cui, N.
    Schimmoller, F.
    Hsu, J. Y.
    He, J.
    De Laurentiis, M.
    Sousa, S.
    Drullinsky, P.
    Jacot, W.
    ANNALS OF ONCOLOGY, 2021, 32 (02) : 197 - 207
  • [27] Metformin (MF) in the prevention of hyperglycemia (HG) in patients (pts) with PIK3CA-mutated, hormone receptor (HR) [+]/HER2[-] advanced breast cancer (ABC) treated with alpelisib (ALP) plus fulvestrant (F): METALLICA
    Llombart Cussac, A.
    Perez-Garcia, J. M.
    Blanch, S.
    Tolosa, P.
    Ruiz Borrego, M.
    Gion Cortes, M.
    Fernadez, A.
    Urruticoechea, A.
    Galve, E.
    Cueva Banuelos, J. F.
    Ponce, J.
    Alonso, J. L.
    Capelan, M.
    Martinez, E.
    Bermejo De Las Heras, B.
    Rojas, B.
    Martos, T.
    Lopez, A.
    Gomez-Peralta, F.
    Cortes, J.
    ANNALS OF ONCOLOGY, 2021, 32 : S77 - S77
  • [28] SEQUence of Endocrine therapy in advanced Luminal Breast cancer (SEQUEL-Breast): A phase 2 study on fulvestrant beyond progression in combination with alpelisib for PIK3CA-mutated, HR+HER2-advanced breast cancer
    Almekinders, Cornelia Am
    Konings, Inge Rhm
    van der Noort, Vincent
    van den Berg, Susan M.
    Bos, Monique Emm
    Dezentje, Vincent O.
    CANCER RESEARCH, 2023, 83 (05)
  • [29] Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study
    Rugo, Hope S.
    Lerebours, Florence
    Ciruelos, Eva
    Drullinsky, Pamela
    Ruiz-Borrego, Manuel
    Neven, Patrick
    Park, Yeon Hee
    Prat, Aleix
    Bachelot, Thomas
    Juric, Dejan
    Turner, Nicholas
    Sophos, Nickolas
    Zarate, Juan Pablo
    Arce, Christina
    Shen, Yu-Ming
    Turner, Stuart
    Kanakamedala, Hemanth
    Hsu, Wei-Chun
    Chia, Stephen
    LANCET ONCOLOGY, 2021, 22 (04): : 489 - 498
  • [30] Evaluation of alpelisib-induced hyperglycemia prophylaxis and associated risk factors in PIK3CA-mutated hormone-receptor positive, human epidermal growth factor-2 negative advanced breast cancer
    Burnette, Sarah E.
    Poehlein, Emily
    Lee, Hui-Jie
    Force, Jeremy
    Westbrook, Kelly
    Moore, Heather N.
    BREAST CANCER RESEARCH AND TREATMENT, 2023, 197 (02) : 369 - 376
12345